New Two-Pronged attack on spreading prostate cancer

NCT ID NCT05893381

Recruiting now Disease control Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Source: ClinicalTrials.gov ↗

Summary

This study is testing if a two-part treatment works better than one to control prostate cancer that has spread to a few spots. Men with 1-3 small metastases will receive either targeted radiotherapy alone or radiotherapy plus a targeted radioactive drug called Lu-PSMA. The goal is to see if the combination keeps the cancer under control longer and delays the need for hormone-blocking therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UO Medicina Nucleare, AUSL della Romagna
RECRUITING

Cesena, FC, 47521, Italy

Contact Email: •••••@•••••
UO Medicina Nucleare, IRCCS IRST
RECRUITING

Meldola, FC, 47014, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER